Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, B- Blockers, Calcium Channel Blockers, Diuretics, Erythropoiesis-Stimulating Agents (ESAs), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region - Global Forecast to 2026

  • Published On : Jun 2018 |
  • Pages : 178 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Chronic Kidney Disease Drugs Market – Insights

Chronic kidney disease (CKD) involves gradual loss of functioning of kidneys. The normal function of kidneys are to filter out and excrete wastes, and excess fluids from the blood are excreted through urine. However, when an individual is suffering from chronic kidney disease, kidneys cannot perform their natural function and wastes, fluids, and electrolytes build up in the body in excess amounts. Signs and symptoms of chronic kidney disease are not apparent until kidney function becomes significantly impaired. The supportive treatment of chronic kidney disease includes delaying the disease progression and kidney damage. Diseases and conditions such as type 1 or type 2 diabetes, high blood pressure, polycystic kidney disease, and recurrent kidney infection leads to chronic kidney disease. Factors that increase risk of chronic kidney disease include diabetes, high blood pressure, smoking, obesity, and others. Management of the disease involves managing the co-morbidities such as blood pressure, diabetes medications, medications to lower cholesterol levels, and anemia treatment. Kidney dialysis and kidney transplant may become a necessity, as the condition becomes worse. There is no direct medication available for the treatment of chronic kidney disease. Chronic kidney diseases may trigger other healthcare issues such as cardiovascular diseases.

High prevalence of diseases leading to chronic kidney diseases are expected to foster growth of the chronic kidney disease drugs market

Diseases such as diabetes and high blood pressure increase the risk of chronic kidney diseases. According to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. are estimated to have chronic kidney disease in 2017. CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease, which indicates the underlying market potential in chronic kidney disease drugs market. Moreover, according to CDC, high blood pressure and diabetes are leading causes of chronic kidney disease. Approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. According to the American Diabetes Association (ADA), in 2015, 30.3 million people in the U.S. were suffering from diabetes. According to CDC, in 2014, around 118,000 people in the U.S. started the treatment for end stage renal disease and as more people become aware of this condition, the number of people for treatment will increase. These factors are expected to boost the market growth over the forecast period.

The global chronic kidney disease drugs market was valued at US$ 12,468.2 million in 2017 and is expected to witness a robust CAGR of 3.1% over the forecast period (2018 – 2026).

Figure 1. Global Chronic Kidney Disease Drugs Market Share, by Region, 2018

chronic kidney disease drugs market

Source: Coherent Market Insights Analysis (2017)

Initiatives taken by government organizations and manufacturers to increase awareness of chronic kidney disease is expected to boost the market growth over the forecast period

Individual government organizations and manufacturers are working towards increasing the awareness of chronic kidney diseases. For instance, American Kidney Fund (AKF) launched comprehensive new kidney disease education portal in May 2018. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). In March 2018, Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Moreover, CVS Health Corporation launched kidney disease initiative in April 2018. In March 2018, Fresenius Medical North America (FMCNA) made a contribution of US$ 40,000 to Kidney School, world’s largest education program for people with chronic kidney disease.

However, delay in the diagnosis of chronic kidney disease is expected to hinder growth of the chronic kidney disease drugs market over the forecast period.

Some major players operating in the chronic kidney disease drugs market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.

Chronic kidney disease can be controlled and prevented from worsening with the help of kidney friendly diet plans and efficiently managing other diseases, which may lead to chronic kidney diseases. For instance, facts such as maintaining a healthy blood pressure, having a low-salt and low-fat diet, control blood sugar, regular exercise, and avoiding smoking and drinking may prevent chronic kidney disease from worsening. Another form of kidney disease is acute kidney disease, which occurs directly due to disorders affecting kidney such as inadequate blood supply and improper urine flow from kidneys. Apart from medication management, other treatment options for end stage renal diseases include dialysis and kidney transplant.

Market Dynamics

The global chronic kidney disease drugs market is driven by factors such as increasing prevalence of chronic kidney disease and high presence of generic drug manufacturers in the market. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. Individual government organizations and manufactures are indulged in research and development as well as increasing awareness about chronic kidney diseases, which is fostering growth of the chronic kidney disease drugs market. In March 2018, the Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Continuous requirement of medication coupled with easy availability of drugs is expected to boost growth of chronic kidney disease drugs market over the forecast period. However, absence of novel treatment option and delay in diagnosis of the disease due to vague symptoms are expected to hinder growth of the chronic kidney disease drugs market.

Key features of the study:

  • This report provides in-depth analysis of chronic kidney disease drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global chronic kidney disease drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the chronic kidney disease drugs market

Detailed Segmentation:

  • Global Chronic Kidney Disease Drugs Market, By Drug Class:
    • ACE Inhibitors
    • B-Blockers
    • Calcium Channel Blockers
    • Diuretics
    • Erythropoiesis-Stimulating Agents (ESAs)
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chronic Kidney Disease Drugs Market, By Region:
    • North America
      • By Drug Class:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Class:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Class:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East
      • By Drug Class:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Amgen, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • AstraZeneca Plc
    • Hoffmann La Roche Ltd.
    • Sanofi S.A.
    • Kissei Pharmaceutical Co. Ltd.
    • AbbVie Inc.
    • GlaxoSmithKline Plc
    • Keryx Biopharmaceuticals, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • PEST Analysis
    • PORTER’s Analysis
    • Regulatory Scenario
  4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • ACE Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • B-Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Calcium Channel Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Diuretics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Erythropoiesis-Stimulating Agents (ESAs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  5. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2016–2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  6. Global Chronic Kidney Disease Drugs Market, By Regions, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Company Profiles
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffman La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Kissei Pharmaceutical Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AbbVie, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Keryx Biopharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 29 market data tables and 47 figures on "Chronic Kidney Disease Drugs Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.